Have a personal or library account? Click to login

Patterns in the Diagnosis and Treatment of Osteoporosis in Men: A Questionnaire-based Survey in Central and Eastern European Countries

Open Access
|Oct 2017

References

  1. 1. Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. J Epidemiol Community Health 1990, 44:241-245.10.1136/jech.44.3.24110606502273364
  2. 2. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010, 95:3-10.10.1210/jc.2009-1740280548320056806
  3. 3. Willson T, Nelson SD, Newbold J et al. The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol 2015. 7:65-76.10.2147/CLEP.S40966429589825657593
  4. 4. Dimai HP, Redlich K, Peretz M et al. Economic burden of osteoporotic fractures in Austria. Health Econ Rev 2012, 2:12.10.1186/2191-1991-2-12342301422827971
  5. 5. Ismail AA, Pye SR, Cockerill WC et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002, 13:565-571.
  6. 6. Ha YC, Park YG, Nam KW, Kim SR. Trend in hip fracture incidence and mortality in Korea: a prospective cohort study from 2002 to 2011. J Korean Med Sci 2015, 30:483-488.10.3346/jkms.2015.30.4.483436697125829818
  7. 7. Cawthon PM, Shahnazari M, Orwoll ES, Lane NE. Osteoporosis in men: findings from the Osteoporotic Fractures in Men Study (MrOS). Ther Adv Musculoskelet Dis 2016, 8:15-27.10.1177/1759720X15621227470741626834847
  8. 8. Alamri SH, Kennedy CC, Marr S et al. Strategies to overcome barriers to implementing osteoporosis and fracture prevention guidelines in long-term care: a qualitative analysis of action plans suggested by front line staff in Ontario, Canada. BMC Geriatr 2015. 15:94.10.1186/s12877-015-0099-8452213126231516
  9. 9. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 16:455-466.10.1016/j.jocd.2013.08.00424183638
  10. 10. Leslie WD, Langsetmo L, Zhou W et al. CaMos Research Group (2014) Choice of lumbar spine bone density reference database for fracture prediction in men and women: a population-based analysis. J Clin Densitom 17:295-300.10.1016/j.jocd.2013.09.003509488224613388
  11. 11. Schousboe JT, Tanner SB, Leslie WD. Definition of osteoporosis by bone density criteria in men: effect of using female instead of male young reference data depends on skeletal site and densitometer manufacturer. J Clin Densitom 2014, 17:301-306.10.1016/j.jocd.2013.09.00824269168
  12. 12. Schousboe JT, Gourlay M, Fink HA et al. Osteoporotic Fractures in Men (MrOS) and Study of Osteoporotic Fractures (SOF) Research Groups (2013) Cost-effectiveness of bone densitometry among Caucasian women and men without a prior fracture according to age and body weight. Osteoporos Int 24:163-177.10.1007/s00198-012-1936-7373971822349916
  13. 13. Nshimyumukiza L, Durand A, Gagnon M et al. An economic evaluation: Simulation of the cost-effectiveness and costutility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res 2013, 28:383-94.10.1002/jbmr.1758358004622991210
  14. 14. Ettinger B, Ensrud KE, Blackwell T et al. Osteoporotic Fracture in Men (MrOS) Study Research Group (2013) Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 24:1185-1193.10.1007/s00198-012-2215-3376703423179575
  15. 15. Ensrud KE, Taylor BC, Peters KW et al. Osteoporotic Fractures in Men Study Group (2014) Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study. BMJ 349: 4120.10.1136/bmj.g4120408083024994809
  16. 16. Giusti A, Bianchi G (2014) Treatment of primary osteoporosis in men. Clin Interv Aging 10:105-115.
  17. 17. Chen L, Wang G, Zheng F, Zhao H, Li H. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int 2015, 26:2355-2363.10.1007/s00198-015-3148-425944731
  18. 18. Chen LX, Zhou ZR, Li YL et al.) Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. PLoS One 10(5):e0128032; doi: 10.1371/journal.pone.0128032. eCollection 2015.10.1371/journal.pone.0128032444410626010450
  19. 19. Liu M, Guo L, Pei Y et al. Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis. Int J Clin Exp Med 2015, 8:3855-3861.
  20. 20. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Oct. Denosumab (Prolia): Treatment to increase bone mass in men with osteoporosis at high risk for fracture; or who have failed or are intolerant to other available osteoporosis therapy [Internet].
  21. 21. Cusano NE, Costa AG, Silva BC, Bilezikian JP. Therapy of osteoporosis in men with teriparatide. J Osteoporos 2011:463675.10.4061/2011/463675320576822132345
  22. 22. Hiligsmann M, Ben Sedrine W, Bruyère O, Reginster JY. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int 2013, 24:2291-2300.10.1007/s00198-013-2272-2370671523371359
  23. 23. Borst SE, Yarrow JF. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. Am J Physiol Endocrinol Metab 2015, 308:E1035-1042.10.1152/ajpendo.00111.2015618963525898953
  24. 24. Svedbom A, Hernlund E, Ivergård M et al. EU Review Panel of IOF Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013, 8:137.10.1007/s11657-013-0137-0388049224113838
  25. 25. Svedbom A, Hernlund E, Ivergård M et al. Epidemiology and economic burden of osteoporosis in Austria. Arch Osteoporos 2013, 8:137; 4-11.10.1007/s11657-013-0136-1388048724113837
  26. 26. Svedbom A, Hernlund E, Ivergård M et al. Epidemiology and economic burden of osteoporosis in Austria. Arch Osteoporos 2013, 8:137; 20-27.10.1007/s11657-013-0136-1
  27. 27. Svedbom A, Hernlund E, Ivergård M et al. Epidemiology and economic burden of osteoporosis in the Czech republic. Arch Osteoporos 2013, 8:137; 35-42.10.1007/s11657-013-0136-1
  28. 28. Svedbom A, Hernlund E, Ivergård M et al. Epidemiology and economic burden of osteoporosis in Hungary. Arch Osteoporos 2013, 8:137; 91-98.10.1007/s11657-013-0136-1
  29. 29. Ivergård M, Svedbom A, Hernlund E et al. Epidemiology and economic burden of osteoporosis in Poland. Arch Osteoporos 2013, 8:137; 154-161.10.1007/s11657-013-0137-0388049224113838
  30. 30. Ivergård M, Svedbom A, Hernlund E et al. Epidemiology and economic burden of osteoporosis in Romania. Arch Osteoporos 2013, 8:137; 170-177.10.1007/s11657-013-0137-0
  31. 31. Ivergård M, Svedbom A, Hernlund E et al. Epidemiology and economic burden of osteoporosis in Slovakia. Arch Osteoporos 2013, 8:137; 178-186.10.1007/s11657-013-0137-0
  32. 32. Ivergård M, Svedbom A, Hernlund E et al. Epidemiology and economic burden of osteoporosis in Slovenia. Arch Osteoporos 2013, 8:137; 187-194.10.1007/s11657-013-0137-0
  33. 33. Boyanov M, Christov V. Prevalence of low central bone mineral density in Bulgarian males. J Men’s Health 2005, 2:318-324.10.1016/j.jmhg.2005.02.002
  34. 34. Kudma K, Krska Z Expense analysis of the proximal femoral fractures treatment. Rozhl Chr 2005, 84:631-634.
  35. 35. Péntek M, Horváth C, Boncz I et al. Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999-2003. Osteoporos Int 2008, 19:243-249.10.1007/s00198-007-0453-617701364
  36. 36. Lakatos P, Tóth E, Szekeres L et al. A csontritkulás kezelésének hatékonysága Magyarországon. Az Országos Egészségbiztosítási Pénztár adatainak elemzése [Efficiency of osteoporosis treatment in Hungary – An analysis of the Hungarian Insurance Company’s data] Lam Kid 2012, 2:5-12.
  37. 37. Grigorie D, Sucaliuc A, Johansson H et al. Incidence of hip fracture in Romania and the development of a Romanian FRAX model. Calcif Tiss Int 2013, 92:429-436.10.1007/s00223-013-9697-723334302
  38. 38. Dzajkovska B, Wertheimer AI, Mrhar A. The burden-of illness study on osteoporosis in the Slovenian female population. Pharm World Sci 2007, 29:404-411.10.1007/s11096-007-9091-517310302
  39. 39. Masaryk P. Hodnotenie rizika osteoporotických zlomenín v primárnej praxi (Fracture risk assessment in primary care). Rheumatologia 2012, 26:127-133.
  40. 40. Lindsay BR, Olufade T, Bauer J, Babrowicz J, Hahn R. Patient-reported barriers to osteoporosis therapy. Arch Osteoporos 2016, 11:19.10.1007/s11657-016-0272-5485170027129487
  41. 41. Kanis JA, Svedbom A, Harvey N, McCloskey EV. The osteoporosis treatment gap. J Bone Miner Res 2014, 29:1926-1928.10.1002/jbmr.230124956507
  42. 42. Kanis JA, McCloskey EV, Johansson H et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23-57.
DOI: https://doi.org/10.1515/amb-2017-0017 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750
Language: English
Page range: 36 - 43
Published on: Oct 23, 2017
Published by: Sofia Medical University
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2017 M. A. Boyanov, E. Czerwinski, A. Shinkov, V. Palička, P. Lakatos, C. Poiana, J. Payer, Z. Killinger, T. Kocjan, O. Lesnyak, G. Holzer, H. Resch, published by Sofia Medical University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.